Clinical Trial Update: Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs [Phase 2]

View source ↗

Summary

Phase 2 trial by GlaxoSmithKline evaluating four formulations of a meningococcal A,C,W-135,Y conjugate vaccine given as a single dose to healthy adolescents age…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal A,C,W-135,Y conjugate vaccine (Meningococcal conjugate vaccine (serogroups A, C, W-135, Y))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED